Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin

1990, Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group, JAMA, 264, 3018, 10.1001/jama.1990.03450230054029 Berenson, 1992, Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study), Am J Cardiol, 70, 851, 10.1016/0002-9149(92)90726-F Tsimikas, 2002, Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century, J Am Coll Cardiol, 40, 2122, 10.1016/S0735-1097(02)02599-8 Aggoun, 2000, Arterial mechanical changes in children with familial hypercholesterolemia, Arterioscler Thromb Vasc Biol, 20, 2070, 10.1161/01.ATV.20.9.2070 Engler, 2003, Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial, Circulation, 108, 1059, 10.1161/01.CIR.0000086345.09861.A0 Mietus-Snyder, 1998, Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy, J Pediatr, 133, 35, 10.1016/S0022-3476(98)70174-X Rodenburg, 2007, Statin treatment in children with familial hypercholesterolemia: the younger, the better, Circulation, 116, 664, 10.1161/CIRCULATIONAHA.106.671016 Wiegman, 2004, Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial, JAMA, 292, 331, 10.1001/jama.292.3.331 Wiegman, 2004, Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia, Lancet, 363, 369, 10.1016/S0140-6736(04)15467-6 Nissen, 2004, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial, JAMA, 291, 1071, 10.1001/jama.291.9.1071 Robinson, 2009, Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk, J Am Coll Cardiol, 53, 316, 10.1016/j.jacc.2008.10.024 Avis, 2007, A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia, Arterioscler Thromb Vasc Biol, 27, 1803, 10.1161/ATVBAHA.107.145151 de Jongh, 2002, Early statin therapy restores endothelial function in children with familial hypercholesterolemia, J Am Coll Cardiol, 40, 2117, 10.1016/S0735-1097(02)02593-7 Macphee, 2005, An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction, Eur Heart J, 26, 107, 10.1093/eurheartj/ehi042 Stafforini, 2009, Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2), Cardiovasc Drugs Ther, 23, 73, 10.1007/s10557-008-6133-8 Tsimikas, 2007, New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease, Arterioscler Thromb Vasc Biol, 27, 2094, 10.1161/01.ATV.0000280571.28102.d4 Kolodgie, 2006, Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis, Arterioscler Thromb Vasc Biol, 26, 2523, 10.1161/01.ATV.0000244681.72738.bc Garza, 2007, Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review, Mayo Clin Proc, 82, 159, 10.1016/S0025-6196(11)60992-0 Sabatine, 2007, Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease, Arterioscler Thromb Vasc Biol, 27, 2463, 10.1161/ATVBAHA.107.151670 Thompson, 2010, Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Lancet, 375, 1536, 10.1016/S0140-6736(10)60319-4 Saougos, 2007, Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2, Arterioscler Thromb Vasc Biol, 27, 2236, 10.1161/ATVBAHA.107.147280 Blencowe, 1995, Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein, J Biol Chem, 270, 31151, 10.1074/jbc.270.52.31151 Karabina, 1996, PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro, Atherosclerosis, 125, 121, 10.1016/0021-9150(96)05872-8 Ky, 2008, The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans, J Am Coll Cardiol, 51, 1653, 10.1016/j.jacc.2008.01.026 O’Donoghue, 2006, Circulation, 113, 1745, 10.1161/CIRCULATIONAHA.105.612630 Koenig, 2006, Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress, Arterioscler Thromb Vasc Biol, 26, 1586, 10.1161/01.ATV.0000222983.73369.c8 Rodenburg, 2006, Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin, J Am Coll Cardiol, 47, 1803, 10.1016/j.jacc.2005.12.047 Koenig, 2009, Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence, Cardiovasc Drugs Ther, 23, 85, 10.1007/s10557-008-6135-6 Tsimikas, 2009, Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study, Eur Heart J, 30, 107, 10.1093/eurheartj/ehn502 Rosenson, 2009, Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease, Cardiovasc Drugs Ther, 23, 93, 10.1007/s10557-008-6148-1 Serruys, 2008, Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque, Circulation, 118, 1172, 10.1161/CIRCULATIONAHA.108.771899 Gazi, 2005, Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma, Clin Chem, 51, 2264, 10.1373/clinchem.2005.058404 Davidson, 2008, Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines, Am J Cardiol, 101, 51F, 10.1016/j.amjcard.2008.04.019 Albert, 2005, The effect of statin therapy on lipoprotein associated phospholipase A2 levels, Atherosclerosis, 182, 193, 10.1016/j.atherosclerosis.2005.05.006 Qiao, 2009, Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits, J Int Med Res, 37, 1029, 10.1177/147323000903700407 Campo, 2004, Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals, Clin Chem, 50, 2077, 10.1373/clinchem.2004.036863 Kiortsis, 2005, Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia, Angiology, 56, 451, 10.1177/000331970505600413 Yamamoto, 2003, Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients, Diabetes Res Clin Pract, 59, 219, 10.1016/S0168-8227(02)00245-0 Mansoub, 2006, Gap analysis of pediatric reference intervals for risk biomarkers of cardiovascular disease and the metabolic syndrome, Clin Biochem, 39, 569, 10.1016/j.clinbiochem.2006.02.013